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Abstract
Cervical cancer is the seventh most frequent cancer worldwide but more than 80% of cases occur
in developing countries. Till date, radiation therapy with external beam and brachytherapy remains
as the core treatment for most stages of cervical cancer. However, radiation treatment protocols
and equipment modelled on the best developed countries can be seldom applied directly to
developing countries owing to financial constraints and lack of qualified personnel, thus, a
substantial proportion of patients do not have access to even palliative radiation therapy.
Treatment options when the standard therapy is either not available or difficult to reproduce in
particular settings is highly desirable with the potential to save lives that otherwise could be lost by
the lack of adequate treatment. These options of treatment ideally had to have show, 1) that these
are not inferior to the "standard" in terms of either survival or quality of life; 2) that these can be
delivered in settings were the "standard" is not available or if available its quality is poor; and 3) that
the treatment option be accepted by the population to be treated.
Based on these considerations, it is obvious that cervical cancer patients, particularly those who
live in countries with limited resources and therefore may not have sufficient radiation therapy
resources are in need of newer therapeutical options. There is now a considerable amount of
information emanating from clinical studies where surgery has a major role in treating this disease.
These forms of "radiation-sparing" treatments include total mesometrial resection that could make
unnecessary the use of adjuvant radiation; neoadjuvant chemotherapy that could avoid the use of
adjuvant radiation in around 85% of patients and preoperative chemoradiation that could make
brachytherapy dispensable. The feasibility and therapeutical value of these potential forms of
management need to be prospectively evaluated.
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Background
Cervical cancer ranks seventh in the list of most frequent
cancers worldwide. However, this tumor is second only to
breast cancer as the most common gynecological neo-
plasm. In addition, more than 80% of cases occur in
developing countries [1] and in a typical developing
country, 60% to 80% of invasive cases present locally
advanced disease [2]. These figures are occurring despite
cervical cancer is a preventable disease with a simple test
such as pap smear. The issue of why pap smear-based
screening campaigns have failed to reduce incidence and
mortality in these countries is beyond the scope of the
present review; however, it is vital to understand why
countries with limited resources have been in general una-
ble to successfully implement well-organized and high
coverage campaigns. It seems then that screening methods
may not equally work in all settings and underscore the
need on performing research to find out which screening
method would be the most appropriate for the specific
social, educational, economical, political and geographic
chararacteristics of countries [3].
In terms of treatment, invasive disease can be divided into
three main groups: 1) early stage, which ranges from
microinvasive disease IA1, IA2 to macroscopic disease
confined to cervix and measuring <4 cm, IB1; 2) locally
advanced FIGO stages IB2-IVA, and 3) IVB and recurrent
disease.
Treatment of early stage cervical cancer
The recommended treatment for IA1 patients is either a
local procedure such as conization or total hysterectomy,
depending on the patient's desire to remain fertile,
whereas for IA2 patients the recommendation is for a rad-
ical hysterectomy which removes parametrial tissue,
upper vagina and pelvic lymph nodes. On average, 8% of
cases show positive pelvic lymph nodes. Because many
women at this disease stage wish and deserve to preserve
fertility, radical trachelectomy is becoming an option for
these patients as well as for IB1 patients [4]. In surgically
treated early-stage cases, the presence in the surgical spec-
imen of a combination of intermediate-risk factors (vas-
cular and lymphatic permeation, tumor size >2 cm, and
deep cervical stroma invasion) or high-risk factors (posi-
tive pelvic lymph nodes, parametrial infiltration, and pos-
itive surgical margins) dictates the use of adjuvant
radiation [5] or chemoradiation, respectively [7].
Current concepts and treatment of locally 
advanced stages
Treatment of locally advanced cervical cancer experienced
no major changes for the nearly 80 years during which
exclusive radiation was considered the standard of care.
However, over the last 20 years, a number of trials testing
concurrent chemoradiation were performed in an attempt
to improve treatment results. Despite this, in 1996 a
National Institutes of Health Consensus Statement on cer-
vical cancer stated that there was no evidence that hydrox-
yurea or any other concomitant chemotherapeutic agent
should be added to pelvic irradiation and incorporated
into standard practice [8]. It was not until 1999 that five
randomized studies including nearly 2,000 patients were
published, demonstrating that survival rate with concom-
itant chemotherapy (RT/CT) based on cisplatin was supe-
rior than that obtained with radiation alone [2].
Afterwards, a meta-analysis based on 19 trials (17 pub-
lished and two unpublished) including 4,580 patients
corroborated these findings, confirming that chemoradia-
tion offers an absolute survival benefit of 12% at 5 years
[9]. Thus, cisplatin-based chemoradiation was largely
accepted as the standard of care for patients with cervical
cancer whose treatment required radiation, except for
patients with co-morbidities who are radiated for stage
IB1 or less. An update of the aforementioned meta-analy-
sis that includes 24 trials (21 published, three unpub-
lished) and 4,921 patients strongly suggests that
chemoradiation improves overall survival and progres-
sion-free survival, whether or not platinum was used, with
absolute benefits of 10 and 13%, respectively. There was,
however, statistical heterogeneity for these outcomes.
There was some evidence that the effect was greater in tri-
als including a high proportion of stage I and II patients.
Chemoradiation also showed significant benefit for local
recurrence and the suggestion of a benefit for distant
recurrence. Acute hematological and gastrointestinal tox-
icity were significantly higher in the concomitant chemo-
radiation group. Treatment-related deaths were rare, but
late effects of treatment were not well-reported; thus, the
impact of chemoradiation on these effects could not be
determined adequately [10].
Thus, the concurrent use of chemoradiation mostly based
on cisplatin or cisplatin 5-fluorouracil has largely been
accepted as the standard. In addition, this concurrent
treatment has been shown to be reproducible in non-
research setting. Several reported experiences of cisplatin
chemoradiation as a routine management consistently
show that the treatment in general is well tolerated and
effective [11,12]. Current research efforts are by now
mostly focused on how to increase the response rate there-
fore the use of radiosensitizer agents such as gemcitabine,
taxanes, camptothecins and others either alone or in com-
bination with cisplatin are undergoing testing in different
phases. In this regard, gemcitabine is the newer cytotoxic
agent with the most extensive evaluation. A randomized
phase II trial demonstrated the superiority of the combi-
nation of standard cisplatin plus gemcitabine over cispla-
tin alone in terms of pathologic complete response rate,
and an ongoing phase III trial that has completed accrualWorld Journal of Surgical Oncology 2006, 4:77 http://www.wjso.com/content/4/1/77
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will eventually confirm these results regarding survival.
On the other hand, several molecular targeted agents pos-
sessing radiosensitizing properties open the way for their
testing either alone or with known cytotoxic radiosensitiz-
ers for cervical cancer. Among the latter, cetuximab, a
monoclonal antibody against the epidermal growth factor
receptor, and a combination of epigenetic therapy agents
are being tested in patients with cervical cancer as an
adjunct to chemoradiation with cisplatin [13].
The situation of radiation resources in the 
developing countries
Radiotherapy is a multidisciplinary speciality that uses
complex equipment and radiation sources for delivery of
treatment. It is estimated that over 2100 megavoltage tel-
etherapy machines are currently installed in developing
countries. This figure is significantly below the estimated
current needs of almost 5000 machines. A conservative
estimate points to a need for about 10,000 machines by
the year 2015. To worsen the picture not only occur limi-
tations in equipments but also there is an enormous need
for qualified professionals (including radiation oncolo-
gists, medical physicists, radiotherapy technicians, radia-
tion protection officers, and maintenance engineers)
capable of operating new radiotherapy equipment. Just as
examples, only 22 out of 56 countries in Africa were
known to have megavoltage therapy and the population
served by each megavoltage machine ranges from 0.6 mil-
lion to 70 million per machine. [14]. In the Asian Pacific
countries as a whole, the situation was not much better,
with significant deficiencies in the availability of all com-
ponents of radiation therapy [15] as it is in Latin America
where not only there is a shortfall of equipment, but also
a major restriction to patient service is an insufficient
number of specialists [16].
Cervical cancer in disadvantaged women accounts for
17% of all female cancers whereas in well developed
countries, cervical cancer accounts for only 4% of female
cancers [1]. These different patterns of cancer have a pro-
found influence on the need for specific radiotherapy
resources. These differences, coupled with the more
advanced stages of cancer present in developing countries,
place different demands on the selection and use of equip-
ment for radiotherapy. The treatment protocols and
equipment modelled on the best developed countries sel-
dom can be applied directly to developing countries
owing to financial constraints and lack of qualified per-
sonnel.
The treatment of cancer is an ever changing field always in
the search for most effective therapies able to increase cure
rate or at least to prolong survival as compared to the ther-
apy considered at the time as standard. Nevertheless, sur-
vival can not always be the unique goal of therapies.
Treatments that while have the same effect upon survival
turn out to be less toxic or have better impact in quality of
life are valuable. Lastly but not the least, to have treatment
options when the standard therapy is either not available
of difficult to reproduce in particular settings is highly
desirable with the potential to save lives that otherwise
could be lost by the lack of adequate treatment. These
options of treatment ideally had to have shown, 1) that
are not inferior to the "standard" in terms of either sur-
vival or quality of life; 2) that can be delivered in setting
were the "standard" is not available of if available its qual-
ity is poor; and 3) that the treatment option be accepted
by the population to be treated.
Based on these considerations, it is obvious that locally
advanced cervical cancer patients, particularly those who
live in countries with limited resources and therefore may
not have sufficient radiation therapy resources are in need
of newer therapeutical options. There is now a considera-
ble amount of information emanating from clinical stud-
ies where surgery has the major role in treating this
disease. These forms of "radiation-sparing" treatments are
here discussed.
Surgery alone without adjuvant radiation
There exists some lack of consensus on what early stage
and locally advanced stages are. It seems that treatment
preferences varies from Institution to Institution. Thus, in
Institutions that routinely employ radical hysterectomy to
treat IB1, IB2 and IIA stages the definition of locally
advanced stages encompases from IIB to IVA as these later
are treated with radiation or chemoradiation as definitive
therapy. On the contrary, Institutions that use radiation or
chemoradiation for IB2 and IIA cases defines locally
advanced disease as stages IB2-IVA. In this context it is
now clear that regardless of the Institutions treatment
preference, the treatment early stage patients can be done
by radical hysterectomy or definitive radiation. This evi-
dence is supported by early trials. One of the first was a
non-randomized trial that started in 1945 in the Univer-
sity of Michigan using either radical hysterectomy or radi-
ation for stage I cases. In this trial 5-year survival was 90%
with any one of these treatments [17]. The first rand-
omized trial was performed between 1956 and 1966 in
119 patients with stage I carcinoma of the cervix by radical
hysterectomy alone (58 patients) or radiotherapy alone
(61 patients). Eighty-one per cent of the patients treated
by radical hysterectomy survived 5 years as compared with
74 per cent of those treated by radiotherapy. The 10 year
survival rates were 75 and 65 per cent, respectively, how-
ever, these differences were not statistically significant.
Complications of treatment were relatively few except for
a greater incidence of urinary tract problems after surgical
treatment; most of these were resolved with restoration of
normal function. Interestingly, since then it was showedWorld Journal of Surgical Oncology 2006, 4:77 http://www.wjso.com/content/4/1/77
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that when recurrence occurred in the surgical series, fur-
ther treatment by radiotherapy offered a reasonable pros-
pect of survival however, radiotherapy failures left
relatively little opportunity for later treatment by surgery
[18]. The most recent randomized trial was reported by an
Italian group in 1997, in which 343 eligible patients were
randomised: 172 to surgery and 171 to radical radiother-
apy. Adjuvant radiotherapy was delivered after surgery for
women with surgical stage pT2b or greater, less than 3
mm of safe cervical stroma, cutthrough, or positive nodes.
After a median follow-up of 87 (range 57–120) months,
5-year overall and disease-free survival were identical in
the surgery and radiotherapy groups (83% and 74%,
respectively, for both groups). Eighty-six women devel-
oped recurrent disease: 42 (25%) in the surgery group and
44 (26%) in the radiotherapy group [19].
Currently, the most accepted criteria for indicating adju-
vant radiation alone is a combination of pathological
findings that place the risk of recurrence as "intermedi-
ate". These are, according to Sedlis [5] the presence of 1)
+CLS (capillary lymphatic space tumor involvement) plus
SI (stromal invasion) of deep 1/3 with any tumor size; 2)
+CLS plus SI of middle 1/3 and ≥2 cm of tumor size; 3)
+CLS plus superficial 1/3 of SI and a tumor size ≥5 cm;
and 4) -CLS plus deep of middle 1/3 with a tumor size ≥4
cm. In an update of the trial, investigators reported that
radiation showed a statistically significant (46%) reduc-
tion in risk of recurrence and a statistically significant
reduction in risk of progression or death (HR = 0.58, 90%
CI = 0.40 to 0.85, p = 0.009) although the improvement
in overall survival (p = 0.074) with radiation did not reach
statistical significance [20]. On the other hand, it has also
been demonstrated that for those cases who have in the
surgical specimens factors confering high-risk of recur-
rence (positive pelvic lymph nodes, disease in parametria
and positive surgical margins) adjuvant cisplatin-based
chemoradiation improves progression-free and overall
survival [7].
Less commonly, some institutions mainly from European
countries and Japan also treat IIB cases with a primary rad-
ical hysterectomy. Although the results are in general
terms roughly similar to those obtained with concurrent
definitive chemoradiation with 5-year survival rates vary-
ing from 55% to 77%, the need for adjuvant radiation can
be as high up to 72% of cases [21,22].
Within the context of this review regarding the issue of
sparing radiation, it can be said that IB1 to IIA cases
elected to be treated with a radical hysterectomy a sub-
stancial fraction of patients will require radiation as com-
plementary treatment. The need of adjuvant radiation
results from the major shortcoming of radical hysterec-
tomy that is the failure within the treatment field. Höckel,
analyzed the loco-regional relapse pattern of patients with
high resolution magnetic resonance imaging and surgical
exploration [23]. He found that most of the pelvic
relapses arose at the dissection sites of the radical hyster-
ectomy and appeared to originate from microscopic or
occult tumor foci within the endopelvic surgical scar.
In rectal cancer, a significant improvement with respect to
postoperative sequelae, loco-regional recurrences, and
survival was achieved by the introduction of the total mes-
orectal excision, a high resolution sharp dissection of the
rectum and its integrated mesentery based on develop-
mentally defined topographic anatomy [24,25]. Based on
this Höekel developed the total mesometrial resection
(TMMR) for the treatment of cervical carcinoma [26-28]
to reduce probability of local relapse and also to avoid the
need of postoperative adjuvant radiation. Total mesome-
trial resection is a high resolution radical hysterectomy
with autonomic nerve preservation based on develop-
mentally defined surgical anatomy. TMMR is character-
ized by en bloc resection of the uterus, proximal vagina
and mesometrium, the integral mesentery covered by
intact bordering lamellae [29], transection of the support-
ing dense subperitoneal connective tissue [30] directly
above the level of the exposed inferior hypogastric plexus,
and extended pelvic/periaortic lymph node dissection
preserving the superior hypogastric plexus. TMMR differs
from the classical radical hysterectomy by consequent
sharp instead of blunt separation of the parietal and vis-
ceral endopelvic planes; exposition of the complete mes-
ometrium by separation from the bladder mesentery;
separate dissection of the mesometrium and the dense
subperitoneal connective tissue supporting the uterus and
proximal vagina with minimal trauma instead of their
composite division as parametrectomy with traumatic
clamps (eg, Wertheim clamps); and exposition and mobi-
lization of the superior hypogastric plexus, hypogastric
nerves and proximal inferior hypogastric plexus.
In 1999, Höckel reported his results of a prospective trial
in patients treated with TMMR for cervical carcinoma
FIGO stages IB, IIA, and selected IIB. By July 2002, 71
patients with cervical cancer stages pT1b1 (48), pT1b2
(8), pT2a (3), pT2b (12) had undergone TMMR without
adjuvant radiation. Fifty-four percent of the patients
exhibited histopathologic high-risk factors. At a median
observation period of 30 months (9–57 months) two
patients relapsed locally, two patients developed pelvic
and distant recurrences and two patients only distant
recurrences. Three patients died from their disease. Grade
1 and 2 complications occurred in 20 patients, no patient
had grade 3 or 4 complications. No severe long-term
impairment of pelvic visceral functions related to auto-
nomic nerve damage was detected. Based on these prelim-
inary results, the author came to the conclusion thatWorld Journal of Surgical Oncology 2006, 4:77 http://www.wjso.com/content/4/1/77
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TMMR achieves a promising therapeutic index by provid-
ing a high probability of locoregional control at minimal
short and long-term morbidity [31].
Taken together, TMMR as a variant of a classical radical
hysterectomy has the potential to reduce the use of adju-
vant radiation treatment and therefore could be suited for
patients living in areas whose radiation resources are poor
however, its value must be tested in randomized trials
before adjvuant radiation can be safely avoided.
Neoadjuvant chemotherapy followed by surgery 
without adjuvant radiation
The negative results of neoadjuvant chemotherapy fol-
lowed by radiation [32], led to the general believe that
induction or neoadjuvant chemotherapy is of no value in
cervical carcinoma. However, a distinction must be made
between the trials that use radiation or surgery to consol-
idate the response to neoadjuvant chemotherapy because
in this tumor type, the modality of local treatment after
induction chemotherapy matters. Despite the lack of ran-
domized trials comparing the current standard chemora-
diation versus radical surgery after induction
chemotherapy, emerging data from a large number of
neoadjuvant trials suggests that surgical resection after
induction chemotherapy could be better as it bypass the
cross-resistance between chemotherapy and radiation,
thus, the disease remaining after chemotherapy, theoreti-
cally could be more effectively treated with surgery.
Accordingly, randomized phase III trials have shown
superior results in terms of survival when locally
advanced (FIGO stages IB2-IVA) are treated with neoadju-
vant chemotherapy followed by surgery as compared to
radiation alone [33-36]. These results have also been ana-
lyzed in a meta-analysis based on individual patient data
from 5 randomized trials conducted worldwide that
included 872 patients and 368 deaths. The overall results
show a highly significant benefit of this modality as com-
pared to radiation alone, with a 36% reduction in the risk
of death, which is equivalent to an absolute improvement
in survival of 15% (8%–21%) at five years, increasing the
survival from 45% to 60%. Similar risk reductions are
observed for progression-free survival, and local and sys-
temic control. This benefit appears to be of the same mag-
nitud to that achieved with the new standard of cisplatin-
based chemoradiation [32].
The results of the meta-analysis on this modality indi-
rectly suggest that it is as effective as the current standard
of cisplatin-based chemoradiation. It should be pointed
out however, that the five studies included in the meta-
analysis [32] used a chemotherapy based on cisplatin plus
"old" drugs such as vincristine and bleomycin, which are
clearly not the most effective as compared to the newer
ones. In a comprehensive review on neoadjuvant chemo-
therapy followed by surgery performed by Eddy [37] it is
shown that the response rates achieved with these regi-
mens vary between 47% to 88%. On the contrary the
response rate achieved with newer drug regimens incorpo-
rating taxanes [38,39], irinotecan [40], vinorelbine [41],
and, gemcitabine [42,43] to platinum compunds seems
higher. These data suggest that it could be possible to
obtain better results if a highly effective drug combination
is used as induction chemotherapy. Up to date, a direct
comparison in a randomized phase III study between this
modality with standard chemoradiation is lacking. We
have recently reported a comparison between two consec-
utive phase II studies in patients with cervical carcinoma
staged from IB2 to IIIB. In the first of these two studies,
neoadjuvant cisplatin gemcitabine followed by surgery
with no adjuvant radiation was employed and, in the sec-
ond, the standard weekly cisplatin concurrent with pelvic
radiation was used. Despite being a non-randomized
comparison, both study groups were well-balanced for the
most relevant clinico-pathological characteristics: histol-
ogy, stage, tumor size, parametrial infiltration, perform-
ance status and pretreatment hemoglobin levels.
Interestingly, at a median follow-up of almost three years,
there are no differences in terms of survival [44], however,
both arms are superior to an historical control treated
with radiation alone [45]. Currently, the EORTC is con-
ducting a multicentric phase III study to compare cispla-
tin-based neoadjuvant chemotherapy followed by surgery
with or without adjuvant radiation versus standard cispl-
atin chemoradiation in stages IB2 to IIB.
Since we are discussing the issue on the ability of neoad-
juvant chemotherapy followed by surgery to avoid or to
spare the use of radiation postoperatively, the issue of the
proper selection of patients and the maximum effort sur-
gery to offer radical hysterectomy to most patients could
not be underestimated. Pooling the results from a litera-
ture review of several neoadjuvant chemotherapy surgery
trials, around 30% of the cases have been treated with
adjuvant pelvic radiation [37]. However, the benefit of
adjuvant radiation after surgery in locally advanced cases
is unknown. Nowadays, the benefit shown of chemoradi-
ation instead of radiation alone as adjuvant treatment of
early staged patients with high-risk factors for recurrence
[7] makes logical the employment of concurrent chemo-
radiation instead of radiation alone as adjuvant treatment
for the locally advanced cases submitted to induction
chemotherapy and radical resection which is feasible in
this patient population [46]. Ideally, no adjuvant radia-
tion (chemoradiation) should be needed without com-
promising the control of the disease if the goal is the avoid
or to keep at minimum the use of radiation. In the current
ongoing randomized comparison between neoadjuvant
chemotherapy followed by surgery (cisplatin-based)
against standard chemoradiaton in IB2-IIB patients, theWorld Journal of Surgical Oncology 2006, 4:77 http://www.wjso.com/content/4/1/77
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resectability rate has approaching 100% and around 15%
have required adjuvant or postoperative chemoradiation.
Neoadjuvant or preoperative chemoradiation 
without brachytherapy
The triple modality of neoadjuvant concurrent chemora-
diation followed by surgery is being studied not only in
cervix uteri carcinoma but in other tumor types [47-51].
The rational behind preoperative chemoradiation is the
obtaining of a major or complete pathological response,
being known that one of the stronger predictors of longer
survival is pathological complete response for almost any
tumor type. Another benefit of this approach is that it
allows one to compare the efficacy of the chemoradiation.
For instance, chemoradiation previous to surgery pro-
duces favorable local control rates, often in excess of 90%
for patients with localized and locally advanced extremity
sarcomas [47]. In a study of 88 patients with advanced rec-
tal cancer, preoperative chemoradiation therapy followed
by definitive surgical resection resulted in decreased recur-
rence and an overall survival of 86% at median follow-up
of 33 months [48]. This modality has also been evaluated
in esophageal cancer. Meluch et al., treated 49 operable
esophageal cancer with preoperative chemoradiation fol-
lowed by esophagectomy, of whom 46% achieved patho-
logical complete response whereas 20% had only
microscopic residual [49] whereas in a study of stage III
non-small cell lung cancer, 79% of 42 patients could
undergo resection, and the five-year survival rate for all
patients and for those who underwent resection were
36.5% and 45.5% respectively, being these figures supe-
rior to reports in literature [50].
Several preoperative chemoradiation studies have been
performed in cervical carcinoma with excellent results in
terms of disease-free and overall survival. Of note, some of
these trials have only used external radiation with or with-
out concurrent chemotherapy whereas other have used
both external beam and brachyterapy before surgery. In
the contex of this review on the avoidability of using
brachytherapy without compromising the results on sur-
vival, we emphasize on this latter issue.
A current paradigm in the treatment of cervical cancer
with radiation therapy is that intracavitary brachytherapy
is an essential component of radical treatment of cervical
cancer. On the other hand, despite that for many years
many institutions routinely used adjuvant extrafacial hys-
terectomy for bulky exophytic or "barrel" shaped tumors,
this procedure as been gradually abandoned due to the
fact that a randomized study showed no benefit on sur-
vival of adjuvant hysterectomy, despite the study sug-
gested that patients with tumors measuring 4 to 6 cm, may
have benefitted from extrafascial hysterectomy [51].
No major research efforts however, have been placed on
the role of a radical hysterectomy after definitive radia-
tion, mainly due to the fact of the undemonstrated utility
of extrafacial hysterectomy as above mentioned, except
for a study reported in 1993 in which uterine cancer
patients deemed to have at high-risk for recurrence under-
went radical hysterectomy after definitive radiation.
Authors conclude that radical hysterectomy after radia-
tion is morbid but may be effective in treating patients
with 1) large cervical tumors, 2) cervical cancer that
responds poorly to radiation, 3) small recurrent cervical
tumors, 4) patients unable to undergo brachytherapy for
cervical cancer, and 5) uterine sarcomas involving the cer-
vix [52].
Data from a few phase II studies of preoperative concur-
rent chemoradiation with no brachytherapy demonstrate
excellent local control rates and survival. In a pilot study
of 40 patients staged IB2 to IVA, Jurado et al., reported the
results of preoperative cisplatin 5-fluorouracil during
external beam radiotherapy to 45Gy with no intracavitary
treatment, however, half of patients received intraopera-
tive radiation. Interestingly, the 9-year local control, dis-
ease-free survival and survival were 86%, 81% and 85%
respectively. As expected, those with pathological com-
plete response (67.5%) fared better [53]. In a study from
Italy, 26 patients (24, IIB and 2, IIIA) were treated with
chemoradiation based on cisplatin and 5-fluorouracil
during external radiation up to 39.6 Gy before radical sur-
gery. A complete pathological response was observed in
54.2%, and a median follow-up of 33 months, the two-
year local control was 91.7% [54]. In the aim to better
assess the role of brachytherapy when radiation is fol-
lowed by hysterectomy, we analyzed the pathological
complete response rates in trials that used either external
beam radiation with or without concurrent chemotherapy
in regard to the use or not of brachytherapy. As inferred
from Table 1, it seems that in the context of stages IB to
IIB, brachytherapy adds nothing in terms of the probabil-
ity of achieving pathological complete response. Overall,
in trials using external beam radiation (EBRT) at doses
between 37.4 to 52 Gy, in common fractions of 1.8 or 2
Gy daily, plus brachytherapy the average complete patho-
logical complete response rate observed is 50% (41%,
44%, 48%, 48%, 69%) [51,55-58], whereas in those using
EBRT at similar doses plus concurrent chemotherapy with
either weekly cisplatin or the combination of cisplatin
and 5-fluorouracil plus brachytherapy, the corresponding
average is 51.1% (38%, 45%, 49%, 52%, 60% and 63%)
[57-62]. Interestingly, in four trials (one of them with to
arms) using EBRT with chemotherapy but no brachyther-
apy, the pathological response rate is essentially the same,
a mean of 51.6% (45%, 45.2%, 46.6%, 54.2 and 67%)
[16,53,63,64]. These data are quite provocative and sug-
gest that for these not so advanced stages, brachytherapyWorld Journal of Surgical Oncology 2006, 4:77 http://www.wjso.com/content/4/1/77
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could be dispensable, however, it must be stressed that
such comparison is based on highly heterogeneous trials
and as such data is only hypothesis generating.
This hypothesis, needs to be tested in phase III trials ran-
domizing patients to brachyterapy or to radical hysterec-
tomy after EBRT concurrent with chemotherapy. These
trials can be fundamented on the fact that as in many
tumors pathological complete response is an excellent
surrogate marker for survival [65-68]. Regarding cervical
cancer we analyzed this issue in a retrospective study
where four cohorts of patients with locally advanced cer-
vical carcinoma (stages IB2-IIIB) included prospectively
in phase II protocols of either neoadjuvant chemotherapy
with 1) cisplatin-gemcitabine, 2) oxaliplatin-gemcitabine,
3) carboplatin-paclitaxel or 4) concurrent EBRT with cis-
platin or cisplatin-gemcitabine followed by radical hyster-
ectomy. In this analysis, one-hundred and fifty three
(86%) of the 178 patients treated within these trials,
underwent radical hysterectomy and were analyzed. Over-
all, the mean age was 44.7 and almost two-thirds were
FIGO stage IIB. Pathological response rates were as fol-
lows: Complete in 60 cases (39.2%), Near-complete in 24
(15.6 %) and partial in 69 cases (45.1%). A higher pro-
portion rate of pCR was observed in patients treated with
chemoradiotherapy compared with patients receiving
only chemotherapy (p = 0.0001). A total of 29 relapses
(18.9%) were documented. The pathological response
was the only factor influencing on relapse, since only 4/60
(6.6%) patients with pCR relapsed, compared with 25/93
(26.8%) patients with viable tumor, either pNear-CR or
pPR (p = 0.001). Overall survival was 98.3% in patients
with pCR versus 83% for patients with either pNear-CR or
pPR (p = 0.009) [69]. In an update (unpublished) of the
results in the preoperative chemoradiation trial, the actu-
arial 5-year survival for the 40 patients treated with EBRT
with cisplatin gemcitabine, is 95% [70]. An additional
advantage of performing radical hysterectomy with pelvic
lymph node dissection is the evidence that after definitive
radiation (EBRT and brachytherapy) around 17% of
patients are left with positive pelvic lymph nodes that go
untreated if not are removed by surgery [61,71].
Yet this triple modality seems promisory regarding local
control and survival, surgical complications, specifically
lymphocysts, fistula and hydronephrosis are more fre-
quent to that reported in patients undergoing either
upfront hysterectomy [72,73] or after neoadjuvant chem-
otherapy [74]. This higher surgical complication rate of
this modality, therefore, should be weighed against the
potential benefit in terms of local and systemic control. In
addition to these observations, the longer time needed to
complete the overall treatment raises the need for quality-
of life evaluations in future studies investigating the role
of preoperative chemoradiation in the treatment of cervi-
cal cancer.
Table 1: Pathological complete response rates in trials of preoperative radiation or chemoradiation with and without brachytherapy.
# of pat [ref] EBRT+BT EBRT/CT+BT EBRT/CT no BT path CR (%)
66 [55] 37.4-40Gy+20Gy 69
61 [56] 46Gy CDDP+27Gy 44
360 [57] 20Gy+40Gy 48
168 [58] 45Gy+30Gy 41
123 [51] 45Gy+30Gy 48
Mean (50.0%)
20 [59] 45Gy CDDP/
5FU+20Gy
60
43 [57] 45Gy CDDP+15Gy 63
35 [60] 45Gy CDDP/
5FU+20Gy
45
175 [58] 45Gy CDDP+30Gy 52
112 [61] 45Gy CDDP/
FU+15Gy
49
175 [62] 44Gy CDDD+16Gy 38
Mean (51.1%)
30 [63] 45Gy CDDP/5FU 46.6
100 [64] 39Gy CDDP/5FU 45.2
24 [53] 39Gy CDDP/5FU 54.2
40 [70] 50Gy CDDP 45
40 [70] 50Gy CDDP/GEM 67
Mean (51.6%)
Most patients were IB2-IIA, some included IIB. Trials whose definition of complete pathological response encompased microscopic residual disease 
were not accounted.World Journal of Surgical Oncology 2006, 4:77 http://www.wjso.com/content/4/1/77
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These results led us to launch a randomized trial that is
ongoing where patients in both arms receive EBRT at dose
of 50 Gy with 2 Gy fraction and are randomized to either
radical hysterectomy or brachytherapy. So far, 34 and 38
are at one year of follow-up after completing treatment
and there have been four failures (2 persistances, 1 local
and 1 local/systemic) in the brachytherapy arm and only
1 systemic failure in the surgical arm. The final results of
this randomized trial would eventually indicate whether
or not brachytherapy can be dispensable in the manage-
ment of IB2 to IIB FIGO stage cervical carcinoma. A sum-
mary of current treatment and proposed "radiation-
sparing managements for IB2-IIB patients is presented in
Table 2.
Conclusion
As for now, external beam radiation and brachytherapy
remain as the core treatment for most stages of cervical
carcinoma. Of late, the results obtained with radiation
were improved by adding concurrent chemoradiation
which has been widely adopted as the newer standard of
management around the world. However, in many devel-
oping countries cervical cancer patients may go untreated
or receive a suboptimal therapy due to lack or poor radia-
tion resources. In this situation, it makes sense to study
the here called "radiation sparing managements" such as
the total mesometrial resection thal could make unneces-
sary the use of adjuvant radiation; the use of neoadjuvant
chemotherapy that could avoid the use of adjuvant radia-
tion in around 85% of patients as well as preoperative
chemoradiation that could make brachytherapy dispensa-
ble. Nevertheless, these alternatives for management of
cervical cancer that decrease or avoid the use of radiation
are far from solving the problem. Access not only to radi-
ation but to cancer treatments is one of the areas of great-
est need in the developing word, particularly for the
countries with the lowest-revenue such as those in the
sub-Saharan Africa. If neoadjuvant chemotherapy or pre-
operative chemoradiation is contemplated, in most low
and middle-income countries the cost of drugs is usually
covered by patients who may found it prohibitive. A sim-
ilar situation can be encountered regarding the availabil-
ity of local or regional cancer centers equiped with
surgical rooms and intensive care units required for radi-
cal surgical procedures. In both cases, qualified medical
and surgical oncologists may also be insufficient or una-
vailable at all.
Much has been written on cancer initiatives for the devel-
oping word. Clearly, the expanding burden of cancer is a
problem that requires a concerted global responses. While
cancer control in developing world is an ambitious long-
term goal, the availability of treatment alternatives suited
to specific settings may represent small steps toward that
end.
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